van Duin D, et al. – Therapeutic impacts of ceftazidime–avibactam versus colistin were assessed in the treatment of Klebsiella pneumoniae carbapenemase (KPC)–producing carbapenem–resistant Enterobacteriaceae (CRE) infections. Findings suggested that ceftazidime–avibactam may be a reasonable alternative treatment option to colistin.